Trial jRCT2031210350
Publication Mukae H, medRxiv (2022) (preprint)
Primary outcome on the report: Change from baseline (day 1, before drug administration) in SARS-CoV-2 viral titer on days 2, 4, 6, 9, 14, and 21 (or study discontinuation).

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.